Related Experiment Video
Updated: May 26, 2026

08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Low-grade osteosarcoma of the mandible
Ramen Sinha1, S K Roy Chowdhury, P K Chattopadhyay
1Division of Oral and Maxillofacial Surgery, Department of Dental Surgery, AFMC, Pune, 411040 India.
Journal of Maxillofacial and Oral Surgery
|December 23, 2011
Summary
Low-grade osteosarcoma (OS) is rare, often misdiagnosed due to subtle histology. Early detection of this malignant bone tumor is crucial for better outcomes.
Area of Science:
- Oncology
- Pathology
- Skeletal Biology
Background:
- Osteosarcoma (OS) is a rare malignant bone tumor originating from primitive bone-forming mesenchyme.
- It most commonly affects the metaphyses of long bones, characterized by bone or osteoid formation.
- Craniofacial osteosarcoma (CFOS) represents a small subset (5-13%) of all OS cases, typically involving the jawbone.
Observation:
- Low-grade osteosarcoma is exceptionally rare, accounting for less than 2% of all reported osteosarcomas.
- These low-grade lesions are frequently misdiagnosed as benign conditions due to their rarity and well-differentiated nature.
- The subtle histological features of low-grade OS often do not correlate with clinical and radiographic presentations, complicating diagnosis.
Findings:
- Low-grade osteosarcoma presents diagnostic challenges due to its rarity and subtle histological characteristics.
- Misdiagnosis as a benign lesion is common, potentially delaying appropriate treatment for this malignant bone tumor.
- The discrepancy between clinical/radiographic findings and histological evidence hinders accurate and timely diagnosis.
Implications:
- Improved diagnostic criteria and awareness are needed for low-grade osteosarcoma, especially in craniofacial locations.
- Early and accurate diagnosis of low-grade OS is critical for effective management and improved patient prognosis.
- Further research into the distinct biological behavior and optimal treatment strategies for low-grade osteosarcoma is warranted.

